SeqOne announced on September 2 that it has entered into a definitive agreement to acquire Congenica, a British company spun out of the Wellcome Sanger Institute.
Founded in 2012, Congenica services more than 25 private and public labs, including multiple NHS Genomics Laboratory Hubs and national programs such as Genomics England and the Hong Kong Genomic Program.
SeqOne’s AI-powered genomic analysis platform, providing clinical decision-support tools that enable molecular laboratories to deliver fast, accurate and scalable analysis of genetic data for applications in oncology, rare and inherited diseases and infectious diseases. The company now serves a global customer base of healthcare providers and biopharmaceutical companies across more than 30 countries.
The acquisition comes on the heels of a period of intense organic growth for SeqOne, which has seen the company double its revenue and expand its international presence from three to more than 30 countries in just 12 months.
SeqOne is committed to ensuring continuity of service and support for all Congenica customers, who will gain access to an expanded and integrated product portfolio. SeqOne will maintain a meaningful U.K. presence at the Wellcome Sanger Institute. The deal terms were undisclosed.
According to data captured in the LevinPro HC database, this transaction marks the 85th Laboratories, MRI and Dialysis transaction of the year, and the 47th in the diagnostic specialty. Throughout all of 2024, there were 122 Laboratories, MRI and Dialysis transactions, 64 of them diagnostic deals.
